What is Humacyte, Inc. (HUMA) stock price today?

Humacyte, Inc. (HUMA) is currently trading at $0.41, down 9.35% today.

What is HUMA P/E ratio?

Humacyte, Inc.'s P/E ratio is -1.00. This is below the market average, suggesting the stock may be undervalued relative to earnings.

What is HUMA return on equity (ROE)?

Humacyte, Inc.'s return on equity (ROE) is -938.20%, indicating how efficiently the company generates profit from shareholders' equity. This is below the typical market average of 12-15%.

What is Humacyte, Inc.'s market cap?

Humacyte, Inc. has a market capitalization of $68.09M.

NASDAQ · Biotechnology

Humacyte, Inc. (HUMA) Stock

$0.41 -9.35% NASDAQ: HUMA Healthcare

Valuation

Metric	Value
Price	$0.41
Market Cap	$68.09M
P/E Ratio	-1.00
P/B Ratio	3.82
P/S Ratio	40.37
EPS (TTM)	$-0.26
52-Week High	$2.55
52-Week Low	$0.40
Dividend Yield	0.00%

Financials & Margins

Metric	Value
ROE	-938.20%
ROA	-70.05%
ROCE	-90.27%
Gross Margin	-7.49%
Operating Margin	-56.49%
Net Margin	-48.41%
Debt/Equity	2.12
Current Ratio	3.78

Annual Financials (USD)

Metric	2021	2022	2023	2024	2025
Revenue	$1.0M	$2.0M	$0	$0	$2.0M
Operating Profit	$-81.0M	$-85.0M	$-100.0M	$-114.0M	$-107.0M
Net Profit	$-26.0M	$-12.0M	$-111.0M	$-149.0M	$-41.0M
EPS	$-0.66	$-0.12	$-1.07	$-1.26	$-0.26
Op Margin	-6429.8%	-5404.4%	—	—	-5271.7%

Balance Sheet (USD)

Metric	2021	2022	2023	2024	2025
Total Assets	$287.0M	$204.0M	$128.0M	$138.0M	$116.0M
Total Liabilities	$164.0M	$87.0M	$115.0M	$191.0M	$113.0M
Cash	$218.0M	$150.0M	$80.0M	$45.0M	$50.0M
Borrowings	$51.0M	$50.0M	$57.0M	$17.0M	$65.0M

Latest News

Humacyte, Inc. (HUMA) Beats Stock Market Upswing: What Investors Need to Know Zacks · Jul 14, 2026 Humacyte Appoints Key Nephrologists as Advisors to Prepare for Planned Commercialization of the ATEV in Dialysis Access GlobeNewswire · Jul 14, 2026 Humacyte, Inc. (HUMA) Stock Sinks As Market Gains: Here's Why Zacks · Jun 30, 2026 Humacyte (HUMA) Stock Fair Value Falls As Split Analyst Views Follow V012 Data Simply Wall St. · Jun 27, 2026 Here's Why Humacyte, Inc. (HUMA) Fell More Than Broader Market Zacks · Jun 25, 2026

Cash Flow (USD)

Metric	2021	2022	2023	2024	2025
Operating Cash Flow	$-81.0M	$-71.0M	$-73.0M	$-98.0M	$-105.0M
Investing Cash Flow	$-8.0M	$4.0M	$-2.0M	$-3.0M	$-2.0M
Financing Cash Flow	$239.0M	$0	$-2.0M	$28.0M	$-88.0M
Net Cash Flow	$178.0M	$-68.0M	$-69.0M	$14.0M	$-44.0M
Free Cash Flow	$-81.0M	$-72.0M	$-76.0M	$-100.0M	$-106.0M

Valuation & Return Ratios

Metric	Value
PEG Ratio	0.00
EV / EBITDA	-0.90
FCF Yield	-113.93%
Quick Ratio	5.74
Interest Coverage	-10.80
Return 1Y	-71.38%
Return 3Y	-76.67%
Return 5Y	-92.95%

Ownership

Insiders Held7.51%

Institutions Held22.31%

Institutions Float Held24.12%

Institutional Holder	Shares	Report Date
Blackrock Inc.	12,316,955	2026-03-31
Vanguard Capital Management LLC	7,158,162	2026-03-31
Antipodes Partners Ltd.	5,723,750	2026-03-31
Great Point Partners LLC	3,750,000	2026-03-31
Geode Capital Management, LLC	3,658,108	2026-03-31

Peer Comparison

Ticker	Price	Change	P/E	Market Cap	Div Yield
ACHVAchieve Life Sciences, Inc.	$7.41	+3.06%	-4.67	$760.70M	0.00%
ARCTArcturus Therapeutics Holdings Inc.	$13.74	+6.76%	-3.91	$390.53M	0.00%
AVIRAtea Pharmaceuticals, Inc.	$5.15	-0.10%	-2.47	$412.14M	0.00%
FHTXFoghorn Therapeutics Inc.	$2.00	+0.50%	-2.11	$117.43M	0.00%
IMRXImmuneering Corporation	$3.94	+5.35%	-3.91	$143.03M	0.00%

About Humacyte, Inc.

Humacyte, Inc. is led by CEO Laura E. Niklason, employs 218 people, headquartered in US, publicly traded since 2020.

Humacyte, Inc. (HUMA) stock trades at $0.41 with a market capitalization of $68.09M. The stock is valued at a price-to-earnings (P/E) ratio of -1.00, price-to-book of 3.82, price-to-sales of 40.37. Over the past 52 weeks the stock has ranged between $0.40 and $2.55, and currently trades 83.9% below its 52-week high.

On profitability, Humacyte, Inc. generates a return on equity (ROE) of -938.20%, return on capital employed of -90.27%, an operating margin of -56.49%, a net profit margin of -48.41%.

Related Healthcare Stocks

LLY Eli Lilly and Company $1179.27 +0.83% JNJ Johnson & Johnson $261.44 +1.93% ABBV AbbVie Inc. $276.47 +1.49% MRK Merck & Company, Inc. Common Stock (new) $145.60 +2.26% UNH UnitedHealth Group Incorporated Common Stock (DE) $379.30 +2.25% NVS Novartis AG $143.75 +0.45% AZN AstraZeneca PLC $159.20 +0.26% TMO Thermo Fisher Scientific Inc $658.02 +0.93% AMGN Amgen Inc. $414.87 +1.82% GILD Gilead Sciences, Inc. $151.17 +2.77% ABT Abbott Laboratories $99.60 +1.13% NVO Novo Nordisk A/S $38.64 +1.20%

Screens featuring this stock

High ROE Healthcare Stocks Low P/E Healthcare Stocks High Net Margin Healthcare Stocks Dividend Healthcare Stocks Low Debt Healthcare Stocks Nasdaq High ROE Stocks All stock screens

Run Stock Screener Investing Guides